SCHEMBL6106883

SCHEMBL6106883

CC(C)(C)OC(=O)N1CCC(C(=O)Nc2cccc(F)c2C(=O)Nc2ccc(Cl)cn2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 3/20 0.49
▸ STS P08842 4/20 0.48
▸ NR3C1 P04150 2/20 0.46
▸ PTPN2 P17706 1/20 0.46
▸ PTPN1 P18031 1/20 0.46
▸ PTPN6 P29350 1/20 0.46
▸ BRD4 O60885 1/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ SCN9A Q15858 1/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ P2RX3 P56373 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ CNR1 P21554 1/20 0.42
▸ CNR2 P34972 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6106348 0.92 F10 (0.51) F10STSNR3C1PTPN2PTPN1
SCHEMBL6108406 0.86 F10 (0.58) F10STSNR3C1PTPN2PTPN1
SCHEMBL6769258 0.85 F10 (0.51) F10STSNR3C1PTPN2PTPN1
SCHEMBL6109270 0.84 F10 (0.68) F10BRD4SMN1; SMN2TDP1SCN9A
Hydrochloric Acid SCHEMBL6107369 0.83 F10 (0.67) F10BRD4SMN1; SMN2TDP1SCN9A
SCHEMBL6107823 0.83 F10 (0.55) F10STSNR3C1PTPN2PTPN1
SCHEMBL6109232 0.83 F10 (0.62) F10STSNR3C1PTPN2PTPN1
SCHEMBL5384090 0.82 F10 (0.71) F10STSNR3C1
SCHEMBL6106396 0.82 F10 (0.54) F10STSNR3C1PTPN2PTPN1
SCHEMBL6107829 0.82 F10 (0.61) F10STSNR3C1PTPN2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7129245-B2 Anticoagulants which act selectively on factor Xa; fast acting; oral; do not interfere with lysis of blood clots ELI LILLY AND COMPANY (US) 2006-10-31 — — US disclosed
US-20050282862-A1 Aromatic amides BEIGHT DOUGLAS W 2005-12-22 — — US disclosed
EP-1140903-B1 AROMATIC AMIDES LILLY CO ELI (US) 2004-08-04 — — EP disclosed
US-6759414-B2 ANTICOAGULANTS WHICH ACT SELECTIVELY ON FACTOR XA; FAST ACTING; ORAL; DO NOT INTERFERE WITH LYSIS OF BLOOD CLOTS ELI LILLY AND COMPANY 2004-07-06 — — US disclosed
US-20040029874-A1 Aromatic amides BEIGHT DOUGLAS WADE (US) 2004-02-12 — — US disclosed
US-6635657-B1 Pyridine derivatives; anticoagulants ELI LILLY AND COMPANY 2003-10-21 — — US disclosed
EP-1140903-A1 AROMATIC AMIDES ELI LILLY AND COMPANY (US) 2001-10-10 — — EP disclosed
WO-2000039118-A1 AROMATIC AMIDES ELI LILLY AND COMPANY (US) 2000-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029874-A1 Aromatic amides F11, F12, F5 F10 12/4885STS 331/4885NR3C1 4435/4885
US-20050282862-A1 Aromatic amides F11, F12, F5 F10 12/4885STS 331/4885NR3C1 4435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback